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Abstract
Although extensively used for the study of left ventricular function, limited
experience exists with the isolated heart model in the evaluation of right ven-
tricular (RV) function. In particular, no published experience exists with this
tool in sugen/hypoxia-induced pulmonary hypertension (SuHx-PH), a fre-
quently used model of severe and progressive PH. We sought to characterize
markers of RV contractile and diastolic function in SuHx-PH and to establish
their relationship with markers of maladaptive RV remodeling. Hearts were
excised from anesthetized Sprague Dawley rats with or without SuHx-PH and
perfused via the aorta using a Langendorff preparation. We explored the
Frank–Starling relationship of RV function (RV developed pressure, dP/dtmax,
and dP/dtmin; all normalized to RV mass) by increasing RV end-diastolic pres-
sure (RVEDP) from 0 to 40 mmHg. Functional studies were complemented
by quantification of RV pro-apoptotic signaling (bcl2/bax), procontractile sig-
naling (apelin), and stress response signaling (p38MAPK activation). Pearson’s
correlation analysis was performed for functional and biochemical parameters.
SuHx-RVs exhibited severe RV dysfunction with marked hypertrophy and
decreased echocardiographic cardiac output. For any given RVEDP, SuHx-
RVs demonstrated less developed pressure and lower dP/dtmax, as well as less
pronounced dP/dtmin, suggestive of decreased contractile and diastolic func-
tion. SuHx-RVs exhibited decreased bcl2/bax ratios, apelin expression, and
p38MAPK activation. Bcl2/bax and apelin RNA abundance correlated posi-
tively with RV developed pressure and dP/dtmax and negatively with dP/dtmin.
p38MAPK activation correlated positively with RV developed pressure. We
conclude that SuHx-RVs exhibit severe contractile and diastolic dysfunction.
Increased pro-apoptotic signaling and attenuated procontractile and stress
response signaling may contribute to these functional alterations.
Introduction
Pulmonary arterial hypertension (PAH) is a progressive
and devastating disease characterized by muscularization,
dysregulated vasoconstriction, and formation of occlusive
lesions in the pulmonary arteries (Rabinovitch 2012; Tuder
et al. 2013a,b). These changes lead to increased right ven-
tricular (RV) afterload and, if left untreated, RV failure
and death (Rabinovitch 2012; Tuder et al. 2013a,b). The
RV initially compensates for the increase in afterload
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through hypertrophy and increased contractile function.
However, as PAH continues to worsen, the RV’s compen-
satory mechanisms fail, resulting in contractile and dias-
tolic dysfunction (Rain et al. 2013; Hsu et al. 2016). These
processes ultimately lead to RV failure and eventually
death (Vonk-Noordegraaf et al. 2013; Vonk Noordegraaf
et al. 2017). Consequentially, in patients with PAH,
decreased RV function is one of the strongest predictors of
death (Humbert et al. 2010; Van De Veerdonk et al.
2011). Despite the critical importance of RV function to
outcomes in PAH, no RV-directed therapies exist. While
the RV and left ventricle (LV) share several similarities,
they are embryologically, structurally, physiologically, bio-
chemically, and electrophysiologically distinct from each
other (Friedberg and Redington 2014). It is therefore not
surprising that treatment strategies beneficial in LV failure
may be detrimental in RV failure (Andersen et al. 2014;
Van Campen et al. 2016). This emphasizes that paradigms
in LV research cannot be extrapolated to the RV and that
specific studies of the RV are necessary. This has recently
been identified as a priority by the NIH and the American
Thoracic Society (Voelkel et al. 2006; Erzurum et al. 2010;
Dweik et al. 2014).
In order to develop RV-targeted therapeutic strate-
gies, a detailed understanding of their effects on RV
function is necessary. While several treatment strategies
have been shown to improve RV function in PAH,
many of these interventions concomitantly target the
pulmonary vasculature, making it challenging to differ-
entiate their pulmonary vascular effects from their
potential effects on intrinsic RV function (Vonk-Noor-
degraaf et al. 2013, 2017). In order to circumvent this
problem, isolated heart models have been used (Nagen-
dran et al. 2007, 2013; Handoko et al. 2009; Piao et al.
2010; Umar et al. 2012; Temple et al. 2016). These
models allow for the detailed study of RV contractile
and diastolic function independent of changes in the
pulmonary vasculature.
However, all these studies have been performed using
the monocrotaline model of PAH, whereas no such stud-
ies have been performed in the sugen/hypoxia (SuHx)
model of PAH. This is of importance, as the SuHx model
currently is widely used for the study of PAH pathogene-
sis and treatment (Stenmark et al. 2009; Maarman et al.
2013). The SuHx model entails a one-time administration
of the VEGF receptor 2 antagonist Su5416 (sugen), fol-
lowed by 3–4 weeks of hypoxia exposure and re-exposure
to room air for 4 or more weeks (Taraseviciene-Stewart
et al. 2001). This results in severe, angioproliferative PH
that mimics human PAH. The model is also characterized
by marked RV dysfunction and a progressive course, both
of which are important features of human PAH. Because
of the widespread use of the SuHx model, there is a need
to better characterize the purported contractile and dias-
tolic function of the SuHx-RV in the isolated heart
model. As many in vivo markers of RV function are pre-
load-dependent, such ex vivo studies would also allow for
evaluation of RV function in a setting that is independent
of preload. A better understanding of the SuHx-RV’s con-
tractile and diastolic properties and their relation to
pathophysiologically relevant molecular signaling path-
ways will (1) provide a better insight into mechanisms of
RV adaptation in this model and (2) facilitate the devel-
opment of RV-specific therapies for patients with PAH
and other types of PH.
We aimed to characterize the contractile and diastolic
function of isolated SuHx-RVs in a Langendorff model
and establish their correlations with pro-apoptotic signal-
ing (bcl-2/bax), procontractile signaling (apelin), and acti-
vation of the stress response regulator p38MAPK. We
report a decrease in RV contractile and diastolic function
in SuHx-RVs and demonstrate novel correlations between
changes in RV contractile and diastolic function and
alterations in bcl-2/bax and apelin expression as well as
p38MAPK activation.
Methods
Animals
Studies were performed in adult male Sprague Dawley
rats (175–200 g; Charles River, Wilmington, MA). Ani-
mals were allowed ad libitum access to food and water
for the duration of the experimentation. All animals
received care in compliance with the Guide for the Care
and Use of Laboratory Animals and followed the Declara-
tion of Helsinki conventions for the use and care of ani-
mals. All experiments were approved by the Institutional
Animal Care and Use Committee of the Indiana Univer-
sity School of Medicine.
Induction of SuHx-PH
Animals received Su5416 (20 mg/kg subcutaneously; dis-
solved in DMSO; Sigma-Aldrich, St Louis, MO) followed
immediately by hypoxia exposure. Hypoxia exposure
occurred in a hypobaric chamber (Patm = 362 mmHg;
equivalent to 10% FiO2) as described previously (Lahm
et al. 2012). After 3 weeks of hypoxia, animals were
returned to room air for another 4 weeks. Age-matched
animals not receiving Su5416 and not undergoing
hypoxia exposure were employed as control (Sham)
groups. Echocardiographic and hemodynamic endpoints
in SuHx and control rats from our laboratory have previ-
ously been described in detail (Frump et al. 2015; Lahm
et al. 2016).
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RV function evaluation by echocardiography
Myocardial structure and function were assessed by echocar-
diography using a high-resolution ultrasound system (Vevo
2100, Visual Sonics, Toronto, Canada). Rats were lightly
anesthetized with 2% isoflurane via nose cone. Images were
obtained in the parasternal two-dimensional short axis and
long axis with an 13- to 24-MHz scan probe. Short-axis M
mode was utilized to measure RV wall thickness. Long-axis
images were used to measure the right ventricular outflow
tract (RVOT) at the level of the pulmonary valve. Stroke
volume (SV) and cardiac output (CO) were determined
using standard formula as follows: SV = VTI 9 3.142 9
(1/ 2 RVOT) and CO = SV 9 heart rate (HR) as described
previously (Frump et al. 2015; Lahm et al. 2016).
Ex vivo isolated perfused heart preparation
To perform the heart perfusion model, hearts were rapidly
isolated and perfused via the aorta at a constant pressure
(60 mmHg) with oxygenated Krebs–Henseleit bicarbonate
buffer (95% O2 + 5% CO2), in a temperature-controlled
(37°C) Langendorff apparatus as previously described
(Watts et al. 2006; Zagorski et al. 2007). Electrodes were
placed at the aorta cannula and cardiac apex, and hearts
were paced at 350 beats/minute (Grass Instruments, S44
stimulator). Parameters of RV systolic and diastolic func-
tion (developed pressure, maximum rate of pressure devel-
opment [dP/dtmax], and maximum rate of relaxation [dP/
dtmin]) were measured through a high-compliance fluid-
filled balloon with a diameter of 3 mm inserted into the
RV and connected to a pressure transducer. Each balloon
was pretested for filling capacity before the beginning of the
experiments. Parameters were recorded using a PowerLab
data acquisition system (AD Instruments, Australia), and
transducer calibration was performed before each experi-
ment following the manufacturer’s instructions. Frank–
Starling relationship was achieved in each heart while filling
the balloon with saline until RV end-diastolic pressure
(RVEDP) increased in 5 mmHg increments from 0 to
40 mmHg. The experimental setup is depicted in Figure 1.
After ex vivo perfusion, RVs were carefully separated from
the left ventricle and septum (LV+S). Fulton index (RV
mass divided by mass of LV plus septum; RV/[LV + S])
was calculated for determination of RV hypertrophy.
Western blot analysis
Immediately after ex vivo analysis, RV tissue was then
washed in ice-cold saline and snap-frozen. RV tissue was
then homogenized using an Omni international tissue grin-
der (Thermo Fisher Scientific, Waltham, MA) in ice-cold
RIPA lysis buffer (Thermo Fisher) containing proteinase
inhibitor cocktail (EMD Millipore/Sigma-Aldrich, St.
Louis, MO) and PhosStop inhibitor cocktail (Roche, Indi-
anapolis, IN). After homogenization, lysate was sonicated
for ten one-second pulses at 100% power and then cen-
trifuged. The supernatant was saved and used as whole lung
lysate. Protein concentration was measured using BCA
Protein Assay (Thermo Fisher). Rabbit polyclonal anti-
phospho-p38MAPK, anti-total p38MAPK, anti-bcl2, and
anti-bax (all used at 1:1000, and from Cell Signaling,
Danvers, MA) and mouse monoclonal anti-Vinculin load-
ing control (1:5000; Calbiochem; Billerica, MA) primary
antibodies were used, all diluted in Pierce Protein-Free T20
Blocking Buffer (Thermo Fisher). All antibodies used have
been extensively validated (Lin et al. 2005; Bernal-Mizrachi
et al. 2006; Bikkavilli et al. 2008; Tang et al. 2008; Slone
et al. 2011; Choi et al. 2016; Jiang et al. 2016; Zhang et al.
2017). Rabbit-HRP (Cell Signaling) and mouse-HRP (KPL,
Gaithersburg, MD) secondary antibodies were diluted
1:2000 in Pierce Protein-Free T20 Blocking Buffer (Thermo
Fisher). Densitometry was performed using ImageJ.
Quantitative real-time PCR
Total RNA from 10 to 30 mg snap-frozen RV tissue was
extracted using the RNeasy Fibrous Tissue kit (Qiagen,
Germantown, MD) and quantified with a NanoDrop
2000 Spectrophotometer (Thermo Scientific, Wilmington,
DE). To generate cDNA for real-time PCR analysis, 1 lg
total RNA was reverse-transcribed using the SuperScript
Figure 1. Overview of Langendorff preparation (isolated perfused
heart) used to evaluate RV function ex vivo. The representative
picture shows a rat heart perfused with oxygenated Krebs–
Henseleit buffer delivered in a retrograde direction down the aorta
at a constant pressure (60 mmHg). A fluid-filled balloon connected
to a pressure transducer is positioned into the RV to acquire
parameters of RV function at increasing RV end-diastolic pressures
(RVEDP; 0–40 mmHg). The temperature electrode is used to
maintain a constant temperature. The pacing electrode is used to
generate a constant heart rate.
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III First-Strand Synthesis System for RT-PCR (Life Tech-
nologies, Thermo Fisher, Carlsbad, CA). Real-time PCRs
were performed using the Applied Biosystems 7500 Real-
time PCR system (Applied Biosystems, Thermo Fisher,
Foster City, CA). TaqMan gene expression assays for Apln
(assay ID: Rn00581093_m1; Thermo Fisher) and Hprt1
(endogenous control; assay ID: Rn01527840_m1; Thermo
Fisher) were used. Changes in mRNA expression were
determined by the comparative CT (2ΔΔCT) method.
Data were expressed as fold change to normoxic controls.
Statistical analysis
Data are presented as means  SEM. Echocardiography,
Fulton index, and biochemical results were compared by
Student’s t-test. Langendorff data were compared with
two-way ANOVA followed by Bonferroni post hoc test.
Correlation analyses were performed by determining
Pearson’s correlation coefficient. The null hypothesis was
rejected at P < 0.05. All tests were performed using
GraphPad Prism software (version 5.0, La Jolla, CA).
Results
SuHx rats exhibit RV hypertrophy and
decreased RV cardiac output in vivo
We first characterized our experimental animals by mea-
suring parameters of RV hypertrophy (RV/[LV + S] ratio
by Fulton index and RV wall thickness by echocardiogra-
phy) and RV function (stroke volume and cardiac output
by echocardiography). As expected, we noted robust
increases in RV hypertrophy in SuHx rats (Fig. 2A and
B), as well as 50–60% decreases in RV stroke volume
(Fig. 2C) and cardiac output (Fig. 2D).
SuHx-RVs exhibit decreased contractile and
diastolic function
We next evaluated the intrinsic function of isolated SuHx-
RVs using the Langendorff preparation. When measuring
developed RVSP, dP/dtmax, and dP/dtmin over a wide range
of RV filling pressures (RVEDP 0–40 mmHg) and compar-
ing values to control rats, SuHx-RVs exhibited modest
increases in developed RVSP (for RVEDP between 15 and
40 mmHg; Fig. 3A) and dP/dtmax (RVEDP 10–40 mmHg;
Fig. 3B), and no significant changes in dP/dtmin (Fig. 3C).
However, when normalizing data for RV mass (reflecting
the abundance in contractile units), we observed 50%
impairments in developed RVSP (Fig. 3D), dP/dtmax
(Fig. 3E), and dP/dtmin (Fig. 3F) in SuHx-RVs. These
alterations were noted over the entire RVEDP range, indi-
cating profound impairments in RV contractile and dias-
tolic function in SuHx-RVs.
SuHx-RVs exhibit increased pro-apoptotic
signaling, decreased apelin mRNA
expression, and decreased p38MAPK
activation
In order to study biochemical alterations that may under-
lie the observed functional impairment, we measured bcl-
Figure 2. SuHx-PH induces RV hypertrophy and decreases RV stroke volume and cardiac output. Fulton index (A) and echocardiographic
parameters of RV remodeling (RV free wall thickness; (B) and function (stroke volume and cardiac output; C and D) in Sham and SuHx-PH rats.
N = 6/group. Values are means  SEM. *P < 0.05 by unpaired t-test.
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2/bax ratio (as a marker of pro-apoptotic signaling), ape-
lin expression (as a marker of procontractile signaling),
and p38MAPK activation (as a marker of stress response
signaling). As previously demonstrated, we noted a
decrease in bcl-2/bax (Fig. 4A) as well as apelin mRNA
(Fig. 4B), suggestive of increased pro-apoptotic signaling
and decreased procontractile signaling. In addition, we
noted a decreased in p38MAPK activation (Fig. 4C), sug-
gesting decreased stress signaling. These decreases were
very robust, ranging from 50% for bcl2/bax to 90% for
apelin.
To rule out confounding effects of the ex vivo prepara-
tion on the biochemical endpoints studied, we compared
p38MAPK abundance and bcl-2/bax ratios between
SuHx-RVs that underwent ex vivo testing in the Langen-
dorff apparatus and freshly isolated SuHx-RVs that did
not undergo ex vivo testing. Of note, while the bcl-2/bax
ratio tended to be slightly decreased in Langendorff vs.
non-Langendorff RVs, we did not find any significant dif-
ferences in these parameters between Langendorff and
non-Langendorff RVs (Fig. 4D), suggesting that the
changes noted are due to PH rather than the ex vivo
preparation.
Markers of RV contractile and diastolic
function correlate with pro-apoptotic,
procontractile, and stress response
signaling parameters
In order to investigate relationships between RV function
parameters and markers of pro-apoptotic, procontractile,
and stress response signaling, we correlated developed
Figure 3. Isolated and perfused right ventricles from SuHx rats exhibit systolic and diastolic impairment. Isolated perfused heart model was
used to evaluate parameters of intrinsic RV function (expressed as developed RV systolic pressure [RVSP], dP/dtmax, and dP/dtmin for various
degrees of RV end-diastolic pressure [RVEDP]). Absolute values are shown in panels (A) (RVSP), (B) (dP/dtmax), and (C) (dP/dtmin). Developed
RVSP, dP/dtmax, and dP/dtmin normalized for RV mass (used as a measure of abundance of contractile units) are shown in panels (D), (E), and
(F), respectively. Note that RV dysfunction (systolic and diastolic) for SuHx-PH is only observed when values are normalized for RV mass. Values
are meansSEM. *P < 0.05 SuHx-PH versus Sham (two-way ANOVA). (G) and (H) show representative tracings for Sham and SuHx-PH groups,
respectively.
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RVSP, dP/dtmax, and dP/dtmin (all at 40 mmHg of
RVEDP and normalized for RV mass) with bcl-2/bax,
apelin mRNA, and p38MAPK activation. We noted mod-
erate-to-strong correlations between developed RVSP and
bcl-2/bax (Fig. 5A) and dP/dtmax and bcl-2/bax (Fig. 5B),
as well as a strong negative correlation between dP/dtmin
and bcl-2/bax (Fig. 5C), indicating more preserved RV
contractile and diastolic function with less pronounced
pro-apoptotic signaling. Similarly, we noted moderate-to-
strong correlations between developed RVSP and apelin
(Fig. 5D) and dP/dtmax and apelin (Fig. 5E), as well as a
strong negative correlation between dP/dtmin and apelin
(Fig. 5F), suggesting more preserved RV contractile and
diastolic function with more preserved apelin expression.
Interestingly, the positive correlations between apelin and
developed RVSP as well as dP/dtmax were the most pro-
nounced among all correlations studied, suggesting a par-
ticular tight connection between apelin expression and
RV contractile function. p38MAPK activation correlated
with developed RVSP (Fig. 5G), but not dP/dtmax or dP/
dtmin. Taken together, these correlations suggest poten-
tially clinically relevant relationships between RV function
parameters and markers of pro-apoptotic, procontractile,
and stress response signaling.
Discussion
Our study is the first to characterize the SuHx-RV in an
isolated heart model. We demonstrate robust decreases in
RV contractile and diastolic function. The correlations of
RV contractile and diastolic function endpoints with
markers of pro-apoptotic signaling, procontractile signal-
ing, and stress response signaling suggest that alterations
in these pathways contribute to RV contractile and dias-
tolic dysfunction.
The Langendorff technique of isolated heart perfusion
has long been used for studies of LV function in models
of acute or chronic LV injury (Bell et al. 2011). Modifica-
tion of the preparation for studies of the RV is technically
more challenging, and the Langendorff technique has only
rarely been used for studies of RV function. Published
studies used the preparation in order to study RV con-
tractile or electrophysiological function (Nagendran et al.
2007, 2013; Handoko et al. 2009; Piao et al. 2010; Umar
et al. 2012; Temple et al. 2016). Of note, all these studies
have been performed in the monocrotaline model of
PAH, a model which only incompletely recapitulates the
human PAH phenotype (Stenmark et al. 2009; Maarman
et al. 2013). In addition, these studies did not evaluate
Figure 4. RVs from SuHx-PH rats exhibit decreased bcl-2/bax ratio, apelin expression, and p38MAPK activation. (A) Western blot analysis of
bcl-2/bax ratio (ratio of prosurvival [bcl-2] to pro-apoptotic [bax] signaling) in RV homogenates measured by Western blot and densitometric
analysis (below Western blot). (B) RV apelin mRNA expression in RVs measured by quantitative real-time RT-PCR. (C) RV expression of phospho-
p38MAPK normalized to total p38MAPK analyzed by Western blot with densitometry below. (D) Comparison of p38MAPK abundance and
bcl-2/bax between SuHx-RVs that underwent ex vivo testing in the Langendorff apparatus (black bars) and freshly isolated SuHx-RVs that did
not undergo ex vivo testing (white bars). N = 6/group in (A–C), n = 4/group in (D). Values are means  SEM. *P < 0.05 by unpaired t-test.
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RV diastolic function, a clinically highly relevant parame-
ter (Rain et al. 2013). We have recently employed this
preparation for characterization of a novel rat model of
chronic thromboembolic PH (CTEPH) (Neto-Neves et al.
2017). However, to the best of our knowledge, the Lan-
gendorff preparation has not yet been employed for the
study of RVs from SuHx rats. This is a significant knowl-
edge gap, as this currently is one of the most widely used
animal models of PH. It is therefore important to thor-
oughly characterize the features of RV function and dys-
function in this model.
Comparison of our results with those performed in
monocrotaline PH is difficult, as these studies focused on
before-and-after interventions rather than describing RV
contractile function for various degrees of RVEDP. In
addition, these studies did not describe diastolic RV func-
tion. We recently employed the isolated heart preparation
in a novel rat model of CTEPH, where we noted extensive
RV contractile dysfunction (also characterized by echocar-
diography and pressure volume relationship in vivo),
similar to what we observed in our current model (Neto-
Neves et al. 2017). However, no diastolic dysfunction was
observed in CTEPH RVs. RV contractile dysfunction was
also previously observed in RVs from rats with moder-
ately severe PH induced by acute pulmonary embolism
(Watts et al. 2006; Zagorski et al. 2007). Of course, these
RVs differ from chronic PH RVs, as they do not exhibit
RV hypertrophy or other compensatory mechanisms.
Our study advances the field by (1) demonstrating that
the Langendorff preparation is feasible in SuHx-PH, (2)
characterizing the contractile and diastolic phenotype of
the SuHx-RV, and (3) identifying novel correlations
between physiological markers of RV function and molec-
ular signaling parameters. While RV contractile and dias-
tolic function have previously been characterized in SuHx
rats in vivo using pressure–volume loops (Da Silva
Goncalves Bos et al. 2017), our study further advances
the field by studying RV function independently of
increases in pulmonary vascular resistance and by investi-
gating developed RVSP, dP/dtmax, and dP/dtmin over a
wide range of RV filling pressures (RVEDP 0–40 mmHg).
Our studies also demonstrate the importance of properly
normalizing the readouts obtained in this model. As
demonstrated in Figure 3, when developed RVSP, dP/
dtmax, and dP/dtmin are not normalized for RV mass
(reflecting the abundance of contractile units), it appears
that SuHx-RVs exhibit better contractile and diastolic
function than controls [similar to what was observed
when investigating contractile function in isolated
monocrotaline RVs (Nagendran et al. 2007, 2013)]. How-
ever, SuHx-RVs exhibit twice the mass than normoxia
controls, resulting in less contractile force and relaxation
per contractile unit. We believe that this normalization
step is important and recommend that markers of con-
tractile and diastolic function are normalized for RV
mass.
One particular advantage of ex vivo preparations such
as the Langendorff is that the effect of acute interventions
on PH-RVs can be studied under tightly regulated condi-
tions, allowing for a detailed and highly controlled char-
acterization of acute interventions on RV function. For
example, drugs, inhibitors, or activators can be added to
the perfusate, allowing for the detailed study of time- or
dose-dependent effects on RV function endpoints. In
Figure 5. Langendorff-derived parameters of RV function correlate with markers of pro-apoptotic signaling, procontractile signaling, and stress
response signaling in Sham and SuHx-PH rats. Developed RVSP, dP/dt max, and dP/dtmin (all at 40 mmHg of RVEDP) were correlated with RV
bcl2/bax ratio (A–C), apelin (D–F), and p38MAPK activation (G) using Pearson’s correlation analysis. Each dot represents one data pair (Sham
represented by open circles, SuHx-PH represented by black squares).
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addition to performing functional studies, the Langen-
dorff technique can also be used for cardiomyocyte isola-
tion. Isolated cardiomyocytes generally have been
understudied in animal models of PH, and more familiar-
ity with the Langendorff preparation may advance this
area. We have successfully utilized this technique in
SuHx-PH rats, allowing for mechanistic studies in cul-
tured cardiomyocytes from untreated or treated animals.
Cardiomyocyte apoptosis has been linked to the devel-
opment of RV failure (Bogaard et al. 2009, 2010). We
therefore evaluated the ratio of the apoptosis inhibitor
bcl-2 and the apoptosis mediator bax, with a lower bcl-2/
bax ratio indicating a shift toward pro-apoptotic signaling
(Misao et al. 1996; Condorelli et al. 1999). As reported
before (Frump et al. 2015; Lahm et al. 2016), we noted a
decreased bcl-2/bax ratio in SuHx-RVs. We now report
the novel finding that decreases in the bcl-2/bax ratio cor-
relate with decreases in contractile and diastolic function,
suggesting that increased pro-apoptotic signaling con-
tributes to RV contractile dysfunction and impaired
relaxation.
Apelin is a secreted peptide expressed in the vasculature
and heart that exerts its effects via the G-protein-coupled
APJ receptor (Andersen et al. 2011; Dalzell et al. 2015).
Apelin plays a critical role in cardiac development, angio-
genesis, prosurvival signaling, nitric oxide-dependent
vasodilation, and inotropic signaling (Andersen et al. 2011;
Dalzell et al. 2015). In the LV, apelin regulates blood vessel
formation after ischemic injury through the upregulation
of cell migration (Wang et al. 2013), progenitor cell
recruitment and differentiation (Li et al. 2012), tube for-
mation, and regulating vascular integrity (Azizi et al.
2015). Interestingly, hypoxic mice infused with apelin exhi-
bit increased cardiac output (Alastalo et al. 2011), making
apelin a promising target for cardiopulmonary diseases. A
role for apelin in PH is suggested by studies demonstrating
that apelin null mice exhibit worsening PH and that circu-
lating apelin is decreased in PAH patients (Chandra et al.
2011). Emerging data suggest a role of apelin in RV failure.
Others and we demonstrated decreases in apelin mRNA
and/or protein in RVs from rats with PH-induced RV fail-
ure (Drake et al. 2011; Frump et al. 2015). We detected
negative correlations between RV apelin abundance and
contractile and diastolic function, suggesting that decreases
in apelin contribute to these processes. This is further sup-
ported by a recent study, which demonstrated stimulatory
effects of apelin and APJ on RV contractile function (Yang
et al. 2017). The mechanisms underlying apelin’s procon-
tractile effects in the RV are currently under investigation
in our laboratory.
The novel finding of a decrease in p38MAPK phospho-
rylation in the SuHx-RV at first sight was surprising.
p38MAPK is a ubiquitous regulator of inflammatory
processes and has been linked to promoting pro-inflam-
matory signaling and pro-inflammatory cytokine activa-
tion (Zarubin and Han 2005). We therefore expected to
see increased p38MAPK activation in our model, in which
we previously demonstrated increased expression of pro-
inflammatory cytokines (Frump et al. 2015). However,
p38MAPK effects are highly stimulus- and cell type-
dependent. For example, p38MAPK signaling has been
shown to promote cell death in some cell lines, but to
enhance survival, cell growth, and differentiation in other
cell types (Zarubin and Han 2005). Specifically,
p38MAPK is a known inducer of the cardioprotective
mediators heat-shock protein 27 and interleukin-6 (Rane
et al. 2003) as well as the cytoprotective mediators heat-
shock protein 70 and carbon monoxide (Kim et al. 2005;
Schallner et al. 2011). Furthermore, p38b MAPK affords
cytoprotection against oxidative stress-induced astrocyte
apoptosis (Shin et al. 2011). A decrease in p38MAPK
activation in the pro-apoptotic environment of the SuHx-
RV is therefore not completely unexpected and is physio-
logically plausible. Lastly, p38MAPK responses may be
time-dependent and differ between various stages of RV
failure development. Future studies will explore these
questions in detail.
A theoretical possibility exists that the process of heart
isolation causes hypoxia stress that is interacting with the
experimental injury and/or confounding by independent
effect. However, several lines of evidence suggest this is
not the case. First, in order to minimize this possibility,
we transferred all hearts from beating in vivo to aortic
perfused within a minute and kept them on iced saline
until perfused. In addition, all SuHx-PH hearts were iso-
lated by the same investigator with the same skill and
rapidity as the controls. Indeed, our healthy animals
showed normal function, suggesting that there is no sig-
nificant injury occurring during the isolation process. Sec-
ond, we noted a higher dP/dtmax and lower dP/dtmin in
SuHx-RVs vs. controls (Fig. 3B and C; not corrected for
RV mass), similar to what was noted by Liu et al. (2017)
in SuHx rats in vivo. Lastly, to rule out biochemical dif-
ferences between SuHx-RVs that underwent ex vivo test-
ing in the Langendorff apparatus and freshly isolated
SuHx-RVs that did not undergo ex vivo testing, we com-
pared p38MAPK abundance and bcl-2/bax ratios between
the two groups. Of note, we did not find any differences
in these parameters between Langendorff and non-Lan-
gendorff RVs (Fig. 4D). While we cannot fully rule out
any subtle differences in the parameters studied or differ-
ences in other endpoints, taken together, these findings
suggest that SuHx-RVs behave similarly ex vivo than
in vivo.”
One difference between the Langendorff preparation
using the RV vs. the LV is that in case of the RV,
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the balloon is inserted into a crescent-shaped rather
than a round cavity. We did not perform any ex vivo
imaging in order to characterize RV cavity dimensions
with the balloon in place, but gross visualization of
the RV with the balloon inflated demonstrated a
maintained crescent shape of the RV. While we can-
not rule out slight changes in RV architecture toward
a more spherical form in the area where the balloon
is inflated, this still allows squeeze from both circum-
ferential and longitudinal contractile fibers, allowing
for assessment of contractile and diastolic function in
a more physiological setting than what is assessed
with isolated muscle strips. In fact, RV volume and
function have been described to correlate well when
measured by intracavitary balloon and echocardiogra-
phy in dogs (Jiang et al. 1994).
Our study has limitations. First, our experimental ani-
mals only included males. We previously reported that
female SuHx-PH animals exhibit better RV function than
their male counterparts (Frump et al. 2015; Lahm et al.
2016). In order to study animals with the most severe RV
failure phenotype, we focused the current study on male
animals. Future studies with the Langendorff preparation
will focus on female RVs and the comparison of RV func-
tion in male vs female animals. Second, while bcl2/bax or
apelin correlated robustly with developed RVSP, dP/dtmax,
and dP/dtmin, p38MAPK only correlated with developed
RVSP. This could indicate that p38MAPK activation only
affects contractile function but does not affect diastolic
function. Alternatively, this observation could be a func-
tion of more variability in p38MAPK activation versus
other parameters, or a result of a type II error. Lastly, our
correlations suggest relationships between the studied
parameters, but not causation. This will be the focus of
future studies.
In summary, this is the first study to demonstrate
decreases in RV contractile and diastolic function in iso-
lated SuHx-RVs using a Langendorff preparation. In addi-
tion, we report increased pro-apoptotic signaling,
decreased apelin expression, and decreased p38MAPK
activation in SuHx-RVs. The correlations between mark-
ers of RV contractile or diastolic function and markers of
pro-apoptotic signaling, procontractile signaling, and
stress response signaling suggest that alterations in these
pathways contribute to contractile and diastolic dysfunc-
tion in SuHx-RVs. Future ex vivo studies of SuHx-RVs
may facilitate the development of novel therapeutic
options for PAH and other types of PH.
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